Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. (Q44652637)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Jose Luis Calleja-Panero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Rafael Esteban

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

M Buti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M A Casado

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Salmerón

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Aguilar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Rueda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

409-419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16423000%20AND%20SRC:MED&resulttype=core&format=json

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Adefovir dipivoxil in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02767.X